Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival

References

• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847–3853
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266
   PubMed Web of Science ®Google Scholar
• Bienz M, Ludwig M, Leibundgut E O, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416–1424
   PubMed Web of Science ®Google Scholar
• Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification. Blood 2007; 109: 431–448
   PubMed Web of Science ®Google Scholar
• el-Deiry W S. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345–357
   PubMed Web of Science ®Google Scholar
• Nelson W G, Kastan M B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815–1823
   PubMed Web of Science ®Google Scholar
• Nahi H, Lehmann S, Bengtzen S, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma 2008; 49: 508–516
   PubMed Web of Science ®Google Scholar
• Bykov V J, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282–288
   PubMed Web of Science ®Google Scholar
• Brooks C L, Gu W. Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 2004; 3: 895–899
   PubMed Web of Science ®Google Scholar
• Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: F115–F177
   PubMed Web of Science ®Google Scholar
• Lowe S W, Sherr C J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77–83
   PubMed Web of Science ®Google Scholar
• Muller-Tidow C, Metzelder S K, Buerger H, et al. Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia. Leukemia 2004; 18: 720–726
   PubMed Web of Science ®Google Scholar
• Sundman-Engberg B, Tidefelt U, Liliemark J, et al. Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo. Cancer Chemother Pharmacol 1990; 25: 252–256
   PubMed Web of Science ®Google Scholar
• Sundman-Engberg B, Tidefelt U, Gruber A, et al. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res 1993; 17: 347–352
   PubMed Web of Science ®Google Scholar
• Rhedin A S, Tidefelt U, Jonsson K, et al. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993; 17: 271–276
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011–4020
   PubMed Web of Science ®Google Scholar
• Andersson A, Johansson B, Lassen C, et al. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004; 72: 307–313
   PubMed Web of Science ®Google Scholar
• Ito A, Lai C H, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20: 1331–1340
   PubMed Web of Science ®Google Scholar
• Fenaux P, Preudhomme C, Lai J L, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246–250
   PubMed Web of Science ®Google Scholar
• Christiansen D H, Andersen M K, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003; 17: 1813–1819
   PubMed Web of Science ®Google Scholar
• Siebert R, Willers C P, Schramm A, et al. Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol 1995; 91: 350–354
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong Y, Yarbrough W G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725–734
   PubMed Web of Science ®Google Scholar
• Cheng K, Grisendi S, Clohessy J G, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: arf inactivation and induction of cellular senescence. Oncogene 2007; 26: 7391–7400
   PubMed Web of Science ®Google Scholar
• Cory A H, Chen J, Cory J G. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Anticancer Res 2006; 26: 1289–1295
   PubMed Web of Science ®Google Scholar
• Nahi H, Merup M, Lehmann S, et al. PRIMA – 1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006; 132: 230–236
   PubMed Web of Science ®Google Scholar
• Bykov V J, Issaeva N, Selivanova G, et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23: 2011–2018
   PubMed Web of Science ®Google Scholar